Astellas Discontinues Development Of Factor Xa Inhibitor Darexaban; Will Not Pursue Anticoagulants
This article was originally published in PharmAsia News
Executive Summary
TOKYO - There is one less oral Factor Xa inhibitor vying for approval after Astellas Pharma Inc. announced it discontinued global development of darexaban for all indications. Unable to find a partner to co-develop the compound, Astellas is bowing out of the anticoagulant space